Quantitative characterization of in vitro bystander effect of antibody-drug conjugates

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 43, Issue 6, 2016, Pages 567-582

  Singh, Aman P ^a   Sharma, Sharad ^a   Shah, Dhaval K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antibody drug conjugates; Bystander effect; Co culture system; Pharmacodynamic modeling; Tumor heterogeneity

Indexed keywords

ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; TRASTUZUMAB VALINE CITRULLINE MMAE CONJUGATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; GREEN FLUORESCENT PROTEIN; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; TRASTUZUMAB-VC-MMAE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BYSTANDER EFFECT; CELL POPULATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG SYNTHESIS; DRUG TARGETING; IC50; IN VITRO STUDY; MATHEMATICAL MODEL; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; MCF-7 CELL LINE; METABOLISM; SYNTHESIS; TIME FACTOR; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BYSTANDER EFFECT; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOCONJUGATES; MCF-7 CELLS; MODELS, BIOLOGICAL; OLIGOPEPTIDES; RECEPTOR, ERBB-2; TIME FACTORS; TRASTUZUMAB;

EID: 84991388060     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-016-9495-8     Document Type: Article

References (29)

1. Peters C, Brown S (2015) Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 35(4):e00225. doi:10.1042/BSR20150089
2. Sohayla RIQ, Robert S (2014) The clinical landscape of antibody-drug conjugates. J Antibody Drug Conjug. doi:10.14229/jadc.2014.8.1.001
3. Lin K, Tibbitts J (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29(9):2354–2366. doi:10.1007/s11095-012-0800-y
4. Chari RV, Miller ML, Widdison WC (2014) Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem 53(15):3796–3827. doi:10.1002/anie.201307628
5. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812–1821. doi:10.1056/NEJMoa1002965
6. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69(5):1229–1240. doi:10.1007/s00280-011-1817-3
7. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063–7070. doi:10.1158/1078-0432.CCR-04-0789
8. Kamath AV, Iyer S (2015) Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res 32(11):3470–3479. doi:10.1007/s11095-014-1584-z
9. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66(8):4426–4433. doi:10.1158/0008-5472.CAN-05-4489
10. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16(3):888–897. doi:10.1158/1078-0432.CCR-09-2069
11. Katz J, Janik JE, Younes A (2011) Brentuximab Vedotin (SGN-35). Clin Cancer Res 17(20):6428–6436. doi:10.1158/1078-0432.CCR-11-0488
12. Kim EG, Kim KM (2015) Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomol Ther 23(6):493–509. doi:10.4062/biomolther.2015.116
13. Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108(3):479–485. doi:10.1038/bjc.2012.581
14. Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Park SY (2012) Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 25(7):938–948. doi:10.1038/modpathol.2012.36
15. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blattler WA, Goldmacher VS (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66(6):3214–3221. doi:10.1158/0008-5472.CAN-05-3973
16. Masuda S, Miyagawa S, Sougawa N, Sawa Y (2015) CD30-targeting immunoconjugates and bystander effects. Nat Rev Clin Oncol 12(4):245. doi:10.1038/nrclinonc.2014.159-c1
17. van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, Loosveld EM, Damming D, Jacobs DC, Rouwette M, Egging DF, van den Dobbelsteen D, Beusker PH, Goedings P, Verheijden GF, Lemmens JM, Timmers M, Dokter WH (2015) The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther 14(3):692–703. doi:10.1158/1535-7163.MCT-14-0881-T
18. Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, Mayer-Bartschmid A, Unterschemmann K, Bruder S, Linden L, Harrenga A, Hauff P, Scholle FD, Muller-Tiemann B, Kreft B, Ziegelbauer K (2014) Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 13(6):1537–1548. doi:10.1158/1535-7163.MCT-13-0926
19. Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR (2016) A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 29(1):117–129. doi:10.1016/j.ccell.2015.12.008
20. Lobo ED, Balthasar JP (2002) Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS Pharm Sci 4(4):E42. doi:10.1208/ps040442
21. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64(3):1094–1101
22. Yang J, Mager DE, Straubinger RM (2010) Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J 12(1):1–10. doi:10.1208/s12248-009-9155-7
23. D’Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 User’s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles
24. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21(2):211–222
25. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T (2016) Bystander killing effect of DS-8201a, a novel anti-HER2 antibody-drug conjugate, in tumors with HER2 heterogeneity. Cancer Sci. doi:10.1111/cas.12966
26. Maass KF, Kulkarni C, Betts AM, Wittrup KD (2016) Determination of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design. AAPS J. doi:10.1208/s12248-016-9892-3
27. Perrino E, Steiner M, Krall N, Bernardes GJ, Pretto F, Casi G, Neri D (2014) Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res 74(9):2569–2578. doi:10.1158/0008-5472.CAN-13-2990
28. Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, Khot A, Shah DK (2016) Evolution of antibody-drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (T-DM1). AAPS J. doi:10.1208/s12248-016-9904-3
29. Shah DK, Haddish-Berhane N, Betts A (2012) Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn 39(6):643–659. doi:10.1007/s10928-012-9276-y